Lincoln Pharmaceuticals' Q3 FY 2025-26 Quarterly Results
- 13 Feb 2026
Result Summary
- Lincoln Pharmaceuticals Ltd reported a 6.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 16.7%.
- Its expenses for the quarter were up by 3.5% QoQ and 15.7% YoY.
- The net profit increased 43.1% QoQ and increased 37.7% YoY.
- The earnings per share (EPS) of Lincoln Pharmaceuticals Ltd stood at 14.28 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 181.47 | 170.60 | 155.52 | 6.4% | 16.7% |
Total Expenses | 146.75 | 141.79 | 126.84 | 3.5% | 15.7% |
Profit Before Tax | 34.72 | 28.81 | 28.68 | 20.5% | 21.1% |
Tax | 6.12 | 8.83 | 7.91 | -30.7% | -22.6% |
Profit After Tax | 28.60 | 19.98 | 20.77 | 43.1% | 37.7% |
Earnings Per Share | 14.28 | 9.98 | 10.37 | 43.1% | 37.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Lincoln Pharmaceuticals Ltd is a company operating in the pharmaceutical industry, primarily involved in the manufacturing and distribution of pharmaceutical products. The company specializes in developing a range of formulations including tablets, capsules, injectables, and syrups aimed at various therapeutic segments. As of the latest available data, Lincoln Pharmaceuticals has been focusing on expanding its product portfolio and enhancing its market presence both domestically and internationally. However, specific recent developments or strategic initiatives for the company are not available based on the data provided.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Lincoln Pharmaceuticals Ltd reported a total income of ₹181.47 crores. This represents a quarter-over-quarter (QoQ) increase of 6.4% from ₹170.60 crores in Q2FY26. Compared to the same quarter in the previous fiscal year (Q3FY25), where the total income was ₹155.52 crores, the year-over-year (YoY) growth stands at 16.7%. The consistent increase in revenue both on a QoQ and YoY basis indicates a positive trend in the company's income generation capabilities for the period under review.
Profitability
The financial data for Q3FY26 shows that Lincoln Pharmaceuticals Ltd achieved a profit before tax (PBT) of ₹34.72 crores, marking a significant QoQ growth of 20.5% from ₹28.81 crores in Q2FY26, and a YoY increase of 21.1% from ₹28.68 crores in Q3FY25. After accounting for taxes amounting to ₹6.12 crores, which decreased by 30.7% QoQ and 22.6% YoY, the profit after tax (PAT) rose to ₹28.60 crores. This PAT reflects a substantial QoQ growth of 43.1% from ₹19.98 crores in the preceding quarter and a 37.7% YoY increase from ₹20.77 crores in the corresponding quarter of the previous year. The earnings per share (EPS) mirrored this trend, increasing from ₹9.98 in Q2FY26 to ₹14.28 in Q3FY26, and from ₹10.37 in Q3FY25, registering the same percentage growth rates as PAT.
Operating Metrics
For Q3FY26, the total expenses for Lincoln Pharmaceuticals Ltd amounted to ₹146.75 crores, which represents a QoQ increase of 3.5% from ₹141.79 crores in Q2FY26, and a YoY increase of 15.7% from ₹126.84 crores in Q3FY25. The growth in expenses, while notable, is lower than the growth in total income, which supports the overall increase in profit margins. The significant decrease in tax expenditure by 30.7% QoQ and 22.6% YoY has also contributed to the enhanced profitability metrics for the quarter. The company appears to be maintaining a strong position in managing its operational costs relative to its revenue growth, as indicated by the financial data for the quarter.